Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HCV: DAA Treatment Linked to Reduced Diabetes Risk

Key clinical point: Study provides further evidence that DAA treatment has non–liver related benefits.

Major finding: DAA treatment was linked to lower diabetes incidence (HR, 0.48).

Study details: Propensity-matched, retrospective analysis (26,043 pairs).

Disclosures: The study was funded by Gilead. Dr. Butt has had research grants from Gilead and Dr. Schooley is on Gilead’s scientific advisory board.


A Butt et al. CROI 2019. Abstract 88.